“Taletrectinib (AB106/DS6051b) demonstrated meaningful clinical activity in advanced ROS1+NSCLC patients who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”
– Sai-Hong Ignatius Ou, M.D., Ph.D.
Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA